Fusion Biopsy Market: USD 0.91 Billion by 2029, 7.1% CAGR

According to Straits Research, the global fusion biopsy market was valued at USD 606.97 million in 2022. The market is projected to reach USD 1603.81 million by 2031, growing at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2023–2031. Fusion biopsy combines images from MRI and ultrasound to produce a detailed prostate image, allowing for precise observation of enlarged or abnormal tissues and guiding the biopsy needle directly into these areas.

Fusion Biopsy Market Categorization

The fusion biopsy market is segmented by biopsy route and end-user:

1. By Biopsy Route
   1. Transrectal
   2. Transperineal
2. By End-User
   1. Hospitals
   2. Diagnostic Centers
   3. Ambulatory Care Centers

The transrectal segment is expected to hold the largest market share due to its accuracy and ease of use.

Geographic Overview

1. North America
   • North America dominated the fusion biopsy market in 2024, holding a 40.8% share.
   • This dominance is attributed to the rising prevalence of prostate cancer in the U.S. and Canada, a large installed base of fusion biopsy units, increasing research activities for prostate cancer treatment, and effective screening programs.
   • The U.S. market is driven by the adoption of advanced diagnostic technologies like transperineal biopsy with 3D MRI fusion, enhancing cancer detection accuracy and reducing infection risks.
2. Europe
   • Europe held the second-largest global market share in 2024.
   • Developed economies and favorable regulatory procedures create significant opportunities for major regional market players.
   • The UK drives the market through pioneering advanced diagnostic technologies such as MRI-US fusion-guided transperineal prostate biopsies (M-TTP).
3. Asia Pacific
   • The Asia Pacific market is expected to grow at the highest CAGR.
   • Growth in this region is due to a large patient population, improving public health awareness, rising cancer awareness, and increasing healthcare investments.
   • China's fusion biopsy market has expanded rapidly due to efforts to improve healthcare services and address the rising burden of prostate cancer.
   • Japan is experiencing growth due to its aging population and government initiatives to improve cancer screening and diagnostic technologies.
4. Middle East and Africa
   • Key countries in this region include South Africa, Saudi Arabia, and the UAE.
   • Market growth is propelled by a large disease burden, increasing privatization of healthcare, and growing penetration of health insurance.
   • The rising incidence of prostate cancer and the surging geriatric population are expected to drive the market.

Download Free Sample Report with Complimentary Analyst Consultation : https://straitsresearch.com/report/fusion-biopsy-market/request-sample

Top Players in the Fusion Biopsy Market

1. Eigen
2. Koninklijke Philips N.V.
3. Hitachi Ltd.
4. Focal Healthcare
5. MedCom
6. ESAOTE SPA
7. KOELIS
8. BK Medical Holding Company Inc.
9. Biobot Surgical Pte Ltd
10. Exact Imaging
11. UC-Care Medical Systems Ltd.

Other notable companies in the fusion biopsy market include GE Healthcare, Siemens Healthineers, Canon Medical Systems Corporation, Medtronic, Hologic, Inc., Varian Medical Systems, Boston Scientific Corporation, Becton, Dickinson and Company, Agilent Technologies, Inc., 3M Company, Carestream Health, and Neusoft Medical Systems Co., Ltd.

Key Unit Economics for Businesses and Startups

Emerging markets are expected to offer significant growth opportunities for players in the fusion biopsy market. Increasing awareness of regular clinical interventions and developing reimbursement policies are likely to boost demand for targeted MR/ultrasound biopsy systems.

Fusion Biopsy Market Operational Factors

Advancements in biopsy devices and a growing preference for minimally invasive procedures are expected to fuel market growth. Fusion biopsy overcomes issues with traditional methods by combining MRI and ultrasound images to guide the biopsy needle accurately into suspected areas, improving accuracy while maximizing tissue yields. This technology enables real-time imaging for efficient tissue sampling while minimizing damage to surrounding healthy tissues.The increasing prevalence of prostate cancer significantly drives the fusion biopsy market. The elderly population contributes to a rise in age-related health conditions like prostate cancer, which predominantly affects older men. As this demographic grows globally, so does the incidence of prostate cancer, leading to increased demand for advanced diagnostic technologies like fusion biopsy.

Why Straits Research?

Straits Research is a leading market research organization, specializing in research, analytics, and advisory services along with providing business6. They offer customized reports tailored to specific needs, including stand-alone sections or country-level analyses6. Straits Research aims to collaborate with customers to deliver a broad spectrum of results through a blend of market and business research approaches4. The firm provides qualitative and quantitative insights into market demand, growth prospects, trends, and regional analysis3.In summary, the global fusion biopsy market is poised for substantial growth driven by technological advancements, increasing prevalence of prostate cancer, and rising healthcare investments. The market segmentation by biopsy route and end-user highlights key areas for development, with North America currently leading in market share. Key players are focusing on product innovation and strategic partnerships to maintain and expand their presence in this dynamic field.

Contact Us:

Email: sales@straitsresearch.com

Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)

Address: 825 3rd Avenue, New York, NY, USA, 10022